During the year, the yields of six funds doubled, all of which were medical-themed funds.

The biopharmaceutical index has been at a record high so far this year, rising 122.44 percent for the year to August 4.
the same time, the Pharmaceutical Theme Fund has been singing all the way.
industry statistics, a total of 6 funds (only A shares) doubled in return during the year, all of which are pharmaceutical and medical theme funds.
The six funds are China Merchants Securities Biopharmaceutical Index Grading, Integrated Healthcare Industry Hybrid A/B, Yfonda Biograding, China Merchants Pharmaceutical Health Industry Stocks, Huitian Fu China Securities Biotech Index (LOF)A, and ICBC Frontier Medical Stocks.
, China Merchants National Certificate biopharmaceuticals in the year income reached 112.80%, the other five within the year benefits are more than 100%.
it is understood that China Merchants National Securities Biopharmaceutical Classification Securities Investment Fund was established on May 27, 2015, the performance benchmark is "China Securities Biopharmaceutical Index x 95.00% plus bank demand deposits x 5.00%".
financial sector fund fixed investment ranking data show that in the past year fixed investment fund income of 93.00 percent, in the last two years fixed investment fund income of 136.38 percent, in the last three years fixed investment fund income of 143.30 percent, the near five-year fixed investment fund income of 157.06 percent.
end of the second quarter of 2020, the top ten heavy stocks of China Merchants National Securities Biopharmaceutical Classification Securities Investment Fund belonged to the pharmaceutical-related industry, accounting for more than 63.7% of the positions.
fund's top ten heavy positions were Changchun Gaoxin (10.41% position ratio), Pharmaceutical Mingkangde (position ratio 9.69 percent), Watson Bio (position ratio 8.94 percent), Zhifei Bio (position ratio 7.31 percent), Hualan Bio (position ratio 6.9 percent). 0%, Kantai Bio (6.38% of positions), Bio (3.89% of positions), Jianfan Bio (3.66% of positions), Huada Gene (3.48% of positions), Tonghua Dongbao (3.08% of positions), the overall concentration of holdings is high.
In terms of china Merchants National Securities Biopharmaceutical Graded Securities Investment Fund, in addition to the drug Mingkangde, the above-mentioned stocks have doubled this year's share price growth, of which Zhifei Bio rose as high as 282.8 percent.
five other funds, Yafonda Biotech heavy stocks are similar.
The fund's heavy stocks include Changchun Gaoxin, Pharmaceutical Mingkangde, Hualan Bio, Watson Bio, Kantai Bio, Tagg Pharmaceuticals, Zhifei Bio, Temple of Heaven Biology, Tonghua Dongbao, Huada Gene, which together account for 63.10% of the total assets of the fund.
it is understood that the YVONDA Biotech Index Graded Securities Investment Fund was established on June 3, 2015, with a performance benchmark of "China Securities Wande Biotech Index x 95.00% plus Bank Demand Deposits x 5.00%".
financial sector fund fixed investment ranking data show that in the past year fixed investment fund income of 63.55 percent, in the last two years fixed investment fund income of 99.35 percent, in the last three years fixed investment fund income of 101.47 percent, in the last five years fixed investment fund income of 106.12 percent.
high yield of China Merchants Pharmaceutical Health Industry Equity Securities Investment Fund has also received attention.
fund was established on January 30, 2015, the performance benchmark is "Pharmaceutical Biology x 80.00% plus China Debt-Composite Index x 20.00%".
financial sector fund fixed investment ranking data show that in the past year fixed investment fund income of 69.32 percent, in the last two years fixed investment fund income of 115.68 percent, in the last three years fixed investment fund income of 130.45 percent, the near five-year fixed investment fund income of 153.59 percent.
Its heavy stock includes Dasan Lin, Jianfan Bio, Huada Gene, Dean Diagnostics, Hualan Bio, Pharmaceutical Mingkangde, Tag Pharmaceuticals, Anglo Medical, Zhifei Bio, Wantay Bio, of which Hualan Biology, Zhifei Biology, Wantai Bio, etc. have been performing brightly in the past month.
.